Tiagabine in anxiety disorders

Bibliography

• GRANT BF, STINSON FS, DAWSON DA et al.: Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch. Gen. Psychiatry (2004) 61:807-816.
   PubMed Web of Science ®Google Scholar
• KESSLER RC, CHIU WT, DEMLER O, MERIKANGAS KR, WALTERS EE: Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch. Gen. Psychiatry (2005) 62:617-627.
   PubMed Web of Science ®Google Scholar
• KESSLER RC, MCGONAGLE KA, ZHAO S et al.: Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch. Gen. Psychiatry (1994) 51:8-19.
   PubMed Web of Science ®Google Scholar
• KESSLER RC, BERGLUND P, DEMLER O, JIN R, MERIKANGAS KR, WALTERS EE: Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch. Gen. Psychiatry (2005) 62:593-602.
   PubMed Web of Science ®Google Scholar
• LYDIARD RB: The role of GABA in anxiety disorders. J. Clin. Psychiatry (2003) 64(Suppl. 3):21-27.
   PubMed Web of Science ®Google Scholar
• NEMEROFF CB: The role of GABA in the pathophysiology and treatment of anxiety disorders. Psychopharmacol. Bull. (2003) 37:133-146.
   PubMedGoogle Scholar
• GODDARD AW, MASON GF, ALMAI A et al.: Reductions in occipital cortex GABA levels in panic disorder detected with 1h-magnetic resonance spectroscopy. Arch. Gen. Psychiatry (2001) 58:556-561.
   PubMed Web of Science ®Google Scholar
• CRESTANI F, LOREZ M, BAER K et al.: Decreased GABAA-receptor clustering results in enhanced anxiety and a bias for threat cues. Nat. Neurosci. (1999) 2:833-839.
   PubMed Web of Science ®Google Scholar
• CHANDRA D, KORPI ER, MIRALLES CP, DE BLAS AL, HOMANICS GE: GABAA receptor gamma 2 subunit knockdown mice have enhanced anxiety-like behavior but unaltered hypnotic response to benzodiazepines. BMC. Neurosci. (2005) 6:30.
   PubMedGoogle Scholar
• SCHWARTZ TL, NIHALANI N, SIMIONESCU M, HOPKINS G: History repeats itself: pharmacodynamic trends in the treatment of anxiety disorders. Curr. Pharm. Des. (2005) 11:255-263.
   Google Scholar
• UHLENHUTH EH, BALTER MB, BAN TA, YANG K: International study of expert judgment on therapeutic use of benzodiazepines and other psychotherapeutic medications: VI. Trends in recommendations for the pharmacotherapy of anxiety disorders, 1992-1997. Depress. Anxiety (1999) 9:107-116.
   PubMedGoogle Scholar
• VAN AMERINGEN M, MANCINI C, PIPE B, BENNETT M: Antiepileptic drugs in the treatment of anxiety disorders: role in therapy. Drugs (2004) 64:2199-2220.
   PubMed Web of Science ®Google Scholar
• STAHL SM, GRADY MM, MORET C, BRILEY M: SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS. Spectr. (2005) 10:732-747.
   PubMed Web of Science ®Google Scholar
• PANDE AC, DAVIDSON JR, JEFFERSON JW et al.: Treatment of social phobia with gabapentin: a placebo-controlled study. J. Clin. Psychopharmacol. (1999) 19:341-348.
   PubMed Web of Science ®Google Scholar
• PANDE AC, FELTNER DE, JEFFERSON JW et al.: Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study. J. Clin. Psychopharmacol. (2004) 24:141-149.
   PubMed Web of Science ®Google Scholar
• STAHL SM: Anticonvulsants as anxiolytics, part 1: tiagabine and other anticonvulsants with actions on GABA. J. Clin. Psychiatry (2004) 65:291-292.
   PubMed Web of Science ®Google Scholar
• BORDEN LA, MURALI DHAR TG, SMITH KE, WEINSHANK RL, BRANCHEK TA, GLUCHOWSKI C: Tiagabine, SK&F 89976-A, CI-966, and NNC-711 are selective for the cloned GABA transporter GAT-1. Eur. J. Pharmacol. (1994) 269:219-224.
   PubMedGoogle Scholar
• FINK-JENSEN A, SUZDAK PD, SWEDBERG MD, JUDGE ME, HANSEN L, NIELSEN PG: The gamma-aminobutyric acid (GABA) uptake inhibitor, tiagabine, increases extracellular brain levels of GABA in awake rats. Eur. J. Pharmacol. (1992) 220:197-201.
   PubMed Web of Science ®Google Scholar
• SUZDAK PD, JANSEN JA: A review of the preclinical pharmacology of tiagabine: a potent and selective anticonvulsant GABA uptake inhibitor. Epilepsia (1995) 36:612-626.
   PubMed Web of Science ®Google Scholar
• SCHMITT U, HIEMKE C: Effects of GABA-transporter (GAT) inhibitors on rat behaviour in open-field and elevated plus-maze. Behav. Pharmacol. (1999) 10:131-137.
   PubMed Web of Science ®Google Scholar
• SCHMITT U, LUDDENS H, HIEMKE C: Behavioral effects of GABA(A) receptor stimulation and GABA-transporter inhibition. Pharmacol. Biochem. Behav. (2000) 65:351-356.
   PubMedGoogle Scholar
• ZWANZGER P, ESER D, PADBERG F et al.: Effects of tiagabine on cholecystokinin-tetrapeptide (CCK-4)-induced anxiety in healthy volunteers. Depress. Anxiety. (2003) 18:140-143.
   PubMedGoogle Scholar
• ZWANZGER P, RUPPRECHT R: Selective GABAergic treatment for panic? Investigations in experimental panic induction and panic disorder. J. Psychiatry Neurosci. (2005) 30:167-175.
   PubMed Web of Science ®Google Scholar
• CRANE D: Tiagabine for the treatment of anxiety. Depress. Anxiety. (2003) 18:51-52.
   PubMed Web of Science ®Google Scholar
• ROSENTHAL M: Tiagabine for the treatment of generalized anxiety disorder: a randomized, open-label, clinical trial with paroxetine as a positive control. J. Clin. Psychiatry (2003) 64:1245-1249.
   PubMed Web of Science ®Google Scholar
• POLLACK MH, ROY-BYRNE PP, VAN AMERINGEN M et al.: The selective GABA reuptake inhibitor tiagabine for the treatment of generalized anxiety disorder: results of a placebo-controlled study. J. Clin. Psychiatry (2005) 66:1401-1408.
   PubMed Web of Science ®Google Scholar
• SCHALLER JL, THOMAS J, RAWLINGS D: Low-dose tiagabine effectiveness in anxiety disorders. MedGenMed. (2004) 6:8.
   PubMedGoogle Scholar
• TAYLOR FB: Tiagabine for posttraumatic stress disorde: a case series of 7 women. J. Clin. Psychiatry (2003) 64:1421-1425.
   PubMed Web of Science ®Google Scholar
• CONNOR KM, DAVIDSON JR, WEISLER RH, ZHANG W, ABRAHAM K: Tiagabine for posttraumatic stress disorder: effects of open-label and double-blind discontinuation treatment. Psychopharmacology (2006) 184:21-25.
   PubMed Web of Science ®Google Scholar
• BERIGAN T: Treatment of posttraumatic stress disorder with tiagabine [letter]. Can. J. Psychiatry (2002) 47:788.
   Google Scholar
• ZWANZGER P, BAGHAI TC, SCHULE C et al.: Tiagabine improves panic and agoraphobia in panic disorder patients. J. Clin. Psychiatry (2001) 62:656-657.
   PubMed Web of Science ®Google Scholar
• NINAN PT, PAPP L, DUNLOP BW. Relapse prevention study of tiagabine in patients with social anxiety disorder. Poster presented at the 158th American Psychiatric Association Annual Meeting. Atlanta (GA) USA (May 21 – 26, 2005).
   Google Scholar
• SCHWARTZ TL: The use of tiagabine augmentation for treatment-resistant anxiety disorders: a case series. Psychopharmacol. Bull. (2002) 36:53-57.
   PubMedGoogle Scholar
• CARPENTER LL, SCHECTER JM, TYRKA AR et al.: Open-label tiagabine monotherapy for major depressive disorder with anxiety. J. Clin. Psychiatry (2006) 67:66-71.
   PubMed Web of Science ®Google Scholar
• SCHWARTZ TL, AZHAR N, HUSAIN J et al.: An open-label study of tiagabine as augmentation therapy for anxiety. Ann. Clin. Psychiatry (2005) 17:167-172.
   PubMedGoogle Scholar
• KHAN A, SCHWARTZ TL. Augmentation of SSRI therapy for GAD with tiagabine. Poster presented at the 157th American Psychiatric Association Annual Meeting. New York (NY) USA (May 1 – 6, 2004).
   Google Scholar
• FLOWERS CM, RACOOSIN JA, KORTEPETER C: Seizure activity and off-label use of tiagabine. N. Engl. J. Med. (2006) 354:773-774.
   Google Scholar
• SCHWARTZ TL, KANG D, KUMARESAN H, CHILTON M, BERTONE F: An open-label study to evaluate switching from an SSRI or SNRI to tiagabine to alleviate antidepressant-induced sexual dysfunction in generalized anxiety disorder. Ann. Clin. Psychiatry (2006) In press.
   Google Scholar
• MONTEJO AL, LLORCA G, IZQUIERDO JA, RICO-VILLADEMOROS F: Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. J. Clin. Psychiatry (2001) 62(Suppl. 3):10-21.
   PubMed Web of Science ®Google Scholar
• ASHTON H, YOUNG AH: GABA-ergic drugs: exit stage left, enter stage right. J. Psychopharmacol. (2003) 17:174-178.
   PubMed Web of Science ®Google Scholar
• SUTTON KG, MARTIN DJ, PINNOCK RD, LEE K, SCOTT RH: Gabapentin inhibits high-threshold calcium channel currents in cultured rat dorsal root ganglion neurones. Br. J. Pharmacol. (2002) 135:257-265.
   PubMed Web of Science ®Google Scholar
• MCCLELLAND D, EVANS RM, BARKWORTH L, MARTIN DJ, SCOTT RH: A study comparing the actions of gabapentin and pregabalin on the electrophysiological properties of cultured DRG neurones from neonatal rats. BMC. Pharmacol. (2004) 4:14.
   Google Scholar
• SANKAR R, DERDIARIAN AT: Vigabatrin. CNS. Drug. Reviews. (1998) 4:260-274.
   Google Scholar
• TRINGALI G, AUBRY JM, MOSCIANESE K et al.: Valproic acid inhibits corticotropin-releasing factor synthesis and release from the rat hypothalamus in vitro: evidence for the involvement of GABAergic neurotransmission. J. Psychiatry Neurosci. (2004) 29:459-466.
   Google Scholar
• ROMEO E, STROHLE A, SPALLETTA G et al.: Effects of antidepressant treatment on neuroactive steroids in major depression. Am. J. Psychiatry (1998) 155:910-913.
   PubMed Web of Science ®Google Scholar
• GRIFFIN LD, MELLON SH: Selective serotonin reuptake inhibitors directly alter activity of neurosteroidogenic enzymes. Proc. Natl. Acad. Sci. USA (1999) 96:13512-13517.
   PubMed Web of Science ®Google Scholar
• STROHLE A, ROMEO E, DI MF et al.: GABA(A) receptor-modulating neuroactive steroid composition in patients with panic disorder before and during paroxetine treatment. Am. J. Psychiatry (2002) 159:145-147.
   PubMed Web of Science ®Google Scholar
• STAHL SM: Independent actions on fear circuits may lead to therapeutic synergy for anxiety when combining serotonergic and GABAergic agents. J. Clin. Psychiatry (2002) 63:854-855.
   Google Scholar
• GODDARD AW, BROUETTE T, ALMAI A, JETTY P, WOODS SW, CHARNEY D: Early coadministration of clonazepam with sertraline for panic disorder. Arch. Gen. Psychiatry (2001) 58:681-686.
   PubMed Web of Science ®Google Scholar
• SEEDAT S, STEIN MB: Double-blind, placebo-controlled assessment of combined clonazepam with paroxetine compared with paroxetine monotherapy for generalized social anxiety disorder. J. Clin. Psychiatry (2004) 65:244-248.
   PubMed Web of Science ®Google Scholar